Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nifurzide is a synthetic nitrofuran derivative and intestinal anti-infectious agent, primarily used as an antimicrobial for the treatment of gastrointestinal infections, especially acute diarrheal diseases caused by bacterial pathogens such as Escherichia coli. It exhibits antibacterial activity against a range of enteric bacteria including Campylobacter, Shigella, Aeromonas, Salmonella, and Yersinia enterocolitica. Nifurzide acts locally in the gut due to its poor solubility and minimal absorption from the gastrointestinal tract; it is not substantially metabolized or systemically distributed. Its mechanism involves binding to bacterial cells and inhibiting their growth at low concentrations or exerting bactericidal effects at higher concentrations. Unlike other nitrofurans, it does not induce significant side effects such as vomiting or monoamine oxidase inhibition[1][3][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nifurzide.